NYSE:COV - Covidien Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$0.0350
Today's Range$0.0350 - $0.0350
52-Week Range$65.97 - $108.57
VolumeN/A
Average Volume3.88 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Covidien Public Limited Company is a healthcare products company. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. The Company's brands include Kendall, Nellcor, Puritan Bennett and Valleylab, among others. It has a presence in more than 70 countries, with products sold in over 150 countries. The Company's segments include Medical Devices and United States Medical Supplies. Medical Devices includes marketing of advanced and general surgical solutions, peripheral vascular and neurovascular therapies, patient monitoring products, and airway and ventilation products. United States Medical Supplies includes products, such as nursing care, medical surgical, SharpSafety and original equipment manufacturer (OEM) products. The Company's products include Surgical Solutions, Vascular Therapies, Respiratory and Patient Care.

Receive COV News and Ratings via Email

Sign-up to receive the latest news and ratings for COV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryHealth Care Equipment
SectorN/A
CUSIPG2554F11
WebN/A
Phone+353-1-4381700

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Covidien (NYSE:COV) Frequently Asked Questions

What is Covidien's stock symbol?

Covidien trades on the New York Stock Exchange (NYSE) under the ticker symbol "COV."

How were Covidien's earnings last quarter?

Covidien Ltd (NYSE:COV) issued its quarterly earnings results on Wednesday, November, 5th. The healthcare company reported $1.15 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.02 by $0.13. The healthcare company earned $2.73 billion during the quarter, compared to analysts' expectations of $2.69 billion. The company's quarterly revenue was up 6.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.91 EPS. View Covidien's Earnings History.

Has Covidien been receiving favorable news coverage?

Press coverage about COV stock has been trending somewhat positive recently, InfoTrie reports. The research group scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Covidien earned a daily sentiment score of 1.5 on InfoTrie's scale. They also gave news headlines about the healthcare company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.

What other stocks do shareholders of Covidien own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Covidien investors own include Pfizer (PFE), Intel (INTC), Chevron (CVX), Johnson & Johnson (JNJ), Celgene (CELG), Boeing (BA), CVS Health (CVS), EMC (EMC), Gilead Sciences (GILD) and JPMorgan Chase & Co. (JPM).

Who are Covidien's key executives?

Covidien's management team includes the folowing people:
  • Gary L. Ellis, President, Chief Executive Officer (Age 61)
  • Charles J. Dockendorff, Chief Financial Officer, Executive Vice President (Age 63)
  • Bryan C. Hanson, Group President, Covidien (Age 50)
  • John H. Masterson, Senior Vice President, General Counsel (Age 54)
  • Michael P. Dunford, Senior Vice President - Human Resources (Age 54)
  • James C. Clemmer, Senior Vice President and President - Medical Supplies Business (Age 53)
  • Amy A. McBride-Wendell, Senior Vice President - Strategy and Business Development (Age 53)
  • Jacqueline F. Strayer, Senior Vice President-Corporate Communications (Age 58)
  • Michael E. Tarnoff, Senior Vice President,Chief Medical Officer (Age 46)
  • Peter L. Wehrly, Senior Vice President, Group President - Developed Markets (Age 57)

How do I buy shares of Covidien?

Shares of COV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Covidien?

Covidien's mailing address is 20 On Hatch Lower Hatch Street, Dublin 2, DUBLIN,, Ireland. The healthcare company can be reached via phone at +353-1-4381700.


MarketBeat Community Rating for Covidien (NYSE COV)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  373 (Vote Outperform)
Underperform Votes:  219 (Vote Underperform)
Total Votes:  592
MarketBeat's community ratings are surveys of what our community members think about Covidien and other stocks. Vote "Outperform" if you believe COV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe COV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel